| 2024 |
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis |
Articolo in rivista |
Vai |
| 2024 |
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? |
Articolo in rivista |
Vai |
| 2023 |
Mapping the landscape of immunonutrition and cancer research: A comprehensive bibliometric analysis on behalf of NutriOnc Research Group |
Articolo in rivista |
Vai |
| 2023 |
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study |
Articolo in rivista |
Vai |
| 2023 |
Healthcare Professional Communication on Sexual Health: A Report from the Italian Working Group on Adolescents and Young Adults with Cancer |
Articolo in rivista |
Vai |
| 2023 |
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices |
Articolo in rivista |
Vai |
| 2023 |
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study |
Articolo in rivista |
Vai |
| 2023 |
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST) |
Articolo in rivista |
Vai |
| 2023 |
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals |
Articolo in rivista |
Vai |
| 2023 |
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis |
Review essay (rassegna critica) |
Vai |
| 2023 |
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study |
Articolo in rivista |
Vai |
| 2023 |
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? |
Articolo in rivista |
Vai |
| 2023 |
Network approach in liquidomics landscape |
Articolo in rivista |
Vai |
| 2023 |
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab |
Articolo in rivista |
Vai |
| 2023 |
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study |
Articolo in rivista |
Vai |
| 2023 |
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) |
Articolo in rivista |
Vai |
| 2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Vai |
| 2023 |
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals |
Nota o commento |
Vai |
| 2023 |
Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience |
Articolo in rivista |
Vai |
| 2023 |
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay |
Articolo in rivista |
Vai |
| 2023 |
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) |
Articolo in rivista |
Vai |
| 2023 |
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations |
Articolo in rivista |
Vai |
| 2022 |
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors |
Articolo in rivista |
Vai |
| 2022 |
Liquid biopsy and immunotherapy: is all that glitter gold? |
Capitolo o Saggio |
Vai |
| 2022 |
Future perspectives |
Capitolo o Saggio |
Vai |
| 2022 |
Molecular tumor board |
Capitolo o Saggio |
Vai |
| 2022 |
Liquid biopsy: a right tool in a right context? |
Capitolo o Saggio |
Vai |
| 2022 |
Current clinically validated applications of liquid biopsy |
Capitolo o Saggio |
Vai |
| 2022 |
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible |
Articolo in rivista |
Vai |
| 2022 |
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement |
Articolo in rivista |
Vai |
| 2022 |
The molecular tumor board: a tool for the governance of precision oncology in the real world |
Articolo in rivista |
Vai |
| 2022 |
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2022 |
Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten |
Articolo in rivista |
Vai |
| 2022 |
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography |
Articolo in rivista |
Vai |
| 2022 |
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) |
Articolo in rivista |
Vai |
| 2022 |
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison |
Articolo in rivista |
Vai |
| 2022 |
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors |
Articolo in rivista |
Vai |
| 2022 |
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study |
Articolo in rivista |
Vai |
| 2022 |
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints |
Articolo in rivista |
Vai |
| 2022 |
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma |
Articolo in rivista |
Vai |
| 2022 |
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies |
Articolo in rivista |
Vai |
| 2022 |
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis |
Articolo in rivista |
Vai |
| 2021 |
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors |
Review essay (rassegna critica) |
Vai |
| 2021 |
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2021 |
Cancer of the Thyroid |
Capitolo o Saggio |
Vai |
| 2021 |
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? |
Articolo in rivista |
Vai |
| 2021 |
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge |
Articolo in rivista |
Vai |
| 2021 |
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) |
Articolo in rivista |
Vai |
| 2021 |
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors |
Articolo in rivista |
Vai |
| 2021 |
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome |
Articolo in rivista |
Vai |
| 2021 |
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon |
Articolo in rivista |
Vai |
| 2021 |
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women |
Articolo in rivista |
Vai |
| 2021 |
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study |
Articolo in rivista |
Vai |
| 2021 |
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study |
Articolo in rivista |
Vai |
| 2021 |
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens |
Articolo in rivista |
Vai |
| 2021 |
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor? |
Articolo in rivista |
Vai |
| 2021 |
Current treatment options for HER2-positive breast cancer patients with brain metastases |
Articolo in rivista |
Vai |
| 2021 |
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2021 |
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies |
Articolo in rivista |
Vai |
| 2021 |
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma |
Recensione in rivista |
Vai |
| 2020 |
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections |
Articolo in rivista |
Vai |
| 2020 |
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis |
Articolo in rivista |
Vai |
| 2020 |
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors |
Articolo in rivista |
Vai |
| 2020 |
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
Articolo in rivista |
Vai |
| 2020 |
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients |
Articolo in rivista |
Vai |
| 2020 |
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes |
Articolo in rivista |
Vai |
| 2020 |
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions |
Articolo in rivista |
Vai |
| 2020 |
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming |
Articolo in rivista |
Vai |
| 2020 |
Recent advances in desmoid tumor therapy |
Articolo in rivista |
Vai |
| 2019 |
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? |
Review essay (rassegna critica) |
Vai |
| 2019 |
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives |
Articolo in rivista |
Vai |
| 2019 |
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma |
Articolo in rivista |
Vai |
| 2019 |
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients |
Articolo in rivista |
Vai |
| 2019 |
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis |
Articolo in rivista |
Vai |
| 2019 |
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2019 |
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
| 2019 |
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? |
Articolo in rivista |
Vai |
| 2019 |
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients |
Articolo in rivista |
Vai |
| 2019 |
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis |
Articolo in rivista |
Vai |
| 2019 |
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 |
Articolo in rivista |
Vai |
| 2019 |
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials |
Articolo in rivista |
Vai |
| 2019 |
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives |
Articolo in rivista |
Vai |
| 2019 |
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) |
Review essay (rassegna critica) |
Vai |
| 2019 |
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) |
Nota o commento |
Vai |
| 2019 |
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients |
Articolo in rivista |
Vai |
| 2018 |
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis |
Articolo in rivista |
Vai |
| 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial |
Articolo in rivista |
Vai |
| 2018 |
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab |
Articolo in rivista |
Vai |
| 2018 |
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin |
Articolo in rivista |
Vai |
| 2018 |
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review |
Articolo in rivista |
Vai |
| 2018 |
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib |
Articolo in rivista |
Vai |
| 2018 |
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential |
Articolo in rivista |
Vai |
| 2017 |
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors |
Articolo in rivista |
Vai |
| 2017 |
Liquid Biopsy in Gynecological Cancers |
Capitolo o Saggio |
Vai |
| 2017 |
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2017 |
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice |
Articolo in rivista |
Vai |
| 2017 |
Liquid Biopsy in Gastrointestinal Stromal Tumor |
Capitolo o Saggio |
Vai |
| 2017 |
Liquid Biopsy in Breast Cancer |
Capitolo o Saggio |
Vai |
| 2016 |
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway |
Review essay (rassegna critica) |
Vai |
| 2016 |
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma |
Articolo in rivista |
Vai |
| 2016 |
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? |
Articolo in rivista |
Vai |
| 2016 |
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report |
Articolo in rivista |
Vai |
| 2016 |
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus |
Articolo in rivista |
Vai |
| 2015 |
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers |
eedings |
Vai |
| 2013 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma |
Articolo in rivista |
Vai |
| 2010 |
Serum follistatin in patients with prostate cancer metastatic to the bone |
Articolo in rivista |
Vai |
| 2009 |
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide |
Abstract in rivista |
Vai |
| 2007 |
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. |
eedings |
Vai |
| 2007 |
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. |
Articolo in rivista |
Vai |
| 2007 |
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and
biomolecular features |
Articolo in rivista |
Vai |
| 2006 |
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report |
eedings |
Vai |
| 2006 |
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. |
eedings |
Vai |
| 2006 |
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread |
eedings |
Vai |
| 2006 |
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. |
Articolo in rivista |
Vai |
| 2006 |
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer |
eedings |
Vai |
| 2006 |
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer |
Articolo in rivista |
Vai |
| 2005 |
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER |
Articolo in rivista |
Vai |
| 2005 |
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer |
eedings |
Vai |
| 2005 |
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico |
Altro |
Vai |
